Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The conversation is about a 21-year-old using finasteride, dermarolling, ketoconazole shampoo, hair growth serums, and exosome therapy to treat early-stage thinning on the crown. They are questioning if these treatments are sufficient to improve hair thickness.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

User DeadRay9 reports good progress on finasteride and ketoconazole, with irregular microneedling. They take 1.25mg finasteride, experienced increased libido, and saw improvements at 3-5 months.

The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.